Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The phrase "Nutritional support via direct absorption of free amino acids" does not refer to a single molecular target but rather describes a **physiological process** mediated by a diverse group of membrane proteins known as **amino acid transporters**. These are primarily members of the solute carrier (SLC) superfamily that facilitate the uptake and distribution of dietary or circulating free amino acids across cell membranes—most notably in intestinal epithelial cells during digestion and absorption. There are multiple families within this group—including neutral, cationic, acidic, branched-chain-specific transporters—each with distinct substrate preferences and tissue distributions. Their coordinated activity is essential for maintaining plasma amino acid homeostasis and supporting cellular metabolism throughout the body. Amino acid transporters play critical roles beyond nutrition; they participate in neurotransmission, immune function, energy metabolism, mTOR signaling regulation, autophagy control, insulin secretion modulation—and their dysregulation is implicated in various diseases such as inherited metabolic disorders (e.g., cystinuria), cancers (where certain SLCs like LAT1/SLC7A5 are upregulated), diabetes mellitus/obesity-related pathologies due to altered nutrient sensing/metabolism. While no clinical therapies currently target these proteins specifically for nutritional support purposes, they remain an area of active investigation both as potential drug targets—especially in oncology—and as biomarkers. Because "Nutritional support via direct absorption of free amino acids" is not itself a molecule or receptor but rather describes a biological process involving many related proteins, it should not be considered a canonical therapeutic target name. The correct approach would be to specify individual **amino acid transporter** subtypes such as "Neutral amino acid transporter ASCT2 (SLC1A5)" or "Cationic amino acid transporter 1 (SLC7A1)" depending on context. Therefore: is_incorrect: true — This entry refers to a physiological process involving multiple molecular entities rather than one defined therapeutic target.
Facilitate or mediate the transmembrane movement of free amino acids via symport or antiport mechanisms
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Amino acid transporter.